|
Leigh Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
It was commonly observed in subjects with chronic progressive external ophthalmoplegia (cPEO) and with primary myopathy without cPEO, but also-although less frequently-in multisystem phenotypes such as MELAS, MERFF, Kearns Sayre syndrome, NARP, MNGIE and Leigh syndrome.
|
30710167 |
2019 |
|
Lupus Erythematosus, Systemic
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Four proteins were significantly different between PMA-NETs from RA and SLE neutrophils (<i>p</i> < 0.05): RNASE2 was higher in RA, whereas MPO, leukocyte elastase inhibitor and thymidine phosphorylase were higher in SLE.
|
30915077 |
2019 |
|
Cardiovascular Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
We also offer insights regarding future studies exploring the role of TYMP in the development of cardiovascular disease as well as in therapy.
|
29108898 |
2018 |
|
Neoplasms, Experimental
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
3'-Deoxy-3'-[<sup>18</sup>F]Fluorothymidine Uptake Is Related to Thymidine Phosphorylase Expression in Various Experimental Tumor Models.
|
28971330 |
2018 |
|
Small cell carcinoma of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
Particularly, 11 proteins involved in tumor proliferation (MCM2, 4, 6, 7, and MSH2), metastasis (RCC2, CORO1C, CHD4, and IPO9), and cancer metabolism (PHGDH and TYMP) are identified as SCLC-specific proteins.
|
29888431 |
2018 |
|
Triple Negative Breast Neoplasms
|
0.010 |
Biomarker
|
disease |
BEFREE |
Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers.
|
29463559 |
2018 |
|
Myocardial infarction, stroke
|
0.010 |
Biomarker
|
disease |
BEFREE |
Since platelet-mediated clot formation is a key event in several fatal diseases, such as myocardial infarction, stroke and pulmonary embolism, understanding TYMP in depth may lead to uncovering novel mechanisms in the development of cardiovascular diseases.
|
29108898 |
2018 |
|
Renal Cell Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
High TP expression and thrombocytosis can be regarded as independent prognostic factors of poor survival in patients with RCC.
|
27532673 |
2017 |
|
Myasthenia Gravis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The chromosome 22 disorder, due to mutations in the nuclear gene TYMP encoding thymidine phosphorylase (TP), leads to the accumulation of thymidine and deoxyuridine, with mitochondrial dysfunction.This report describes a patient with an MNGIE-like syndrome with a heterozygous TYMP mutation who showed marked, but transient improvement postallogeneic haematopoietic stem cell transplantation (HSCT).The patient, showing ptosis and ophthalmoplegia, was initially managed for myasthenia gravis.
|
28765176 |
2017 |
|
Mixed sensory-motor polyneuropathy
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
POLG mutations cause a potentially painful, axonal/mixed, mainly sensory polyneuropathy; TYMP mutations lead to a demyelinating sensory-motor polyneuropathy; SURF1 mutations are associated with a demyelinating/mixed sensory-motor polyneuropathy.
|
27020842 |
2017 |
|
Bone Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
A recent study implicates thymidine phosphorylase in myeloma-induced bone disease and suggests that inhibiting the enzyme may be a viable therapeutic option.
|
27658717 |
2016 |
|
Multiple Myeloma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thymidine phosphorylase exerts complex effects on bone resorption and formation in myeloma.
|
27559096 |
2016 |
|
Gonorrhea
|
0.010 |
Biomarker
|
disease |
BEFREE |
We analyzed the expression levels of fluoropyrimidine-metabolizing enzymes (thymidylate synthase [TS], dihydropyrimidine dehydrogenase [DPD], thymidine phosphorylase [TP] and orotate phosphoribosyltransferase [OPRT]) to identify potential biomarkers related to treatment outcomes in gastric cancer (GC) patients receiving adjuvant S-1 chemotherapy.
|
25793299 |
2015 |
|
Liver neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Levels of TYMP and TK1 in the liver tumor tissues were significantly higher than those of normal liver tissues.
|
25881156 |
2015 |
|
Ethylmalonic encephalopathy
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Here, we will review two peculiar mitochondrial disorders, ethylmalonic encephalopathy (EE) and mitochondrial neurogastrointestinal encephalomyopathy (MNGIE), caused by mutations in the ETHE1 and TYMP nuclear genes, respectively.
|
26194912 |
2015 |
|
Arteriosclerosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Platelets contain abundant thymidine phosphorylase (TYMP), which is highly expressed in diseases with high risk of thrombosis, such as atherosclerosis and type II diabetes mellitus.
|
25287063 |
2014 |
|
Atherosclerosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Platelets contain abundant thymidine phosphorylase (TYMP), which is highly expressed in diseases with high risk of thrombosis, such as atherosclerosis and type II diabetes mellitus.
|
25287063 |
2014 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Platelets contain abundant thymidine phosphorylase (TYMP), which is highly expressed in diseases with high risk of thrombosis, such as atherosclerosis and type II diabetes mellitus.
|
25287063 |
2014 |
|
bone destruction
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The induction of thymidine phosphorylase enhanced the expression of CXCL10, which may contribute to the Th1 phenotype and bone destruction observed in RA.
|
24574215 |
2014 |
|
Graft-vs-Host Disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In addition, the TYMP genotype of donors was associated with the risk of chronic graft-versus-host disease (GVHD)-carriers of the minor allele being at an increased risk of developing this complication ([HR] = 1.7; P = 0.039).
|
23813863 |
2013 |
|
Stage III Colorectal Cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
The magnitude of the intratumoral TP/DPD enzyme ratio may be a potential indicator for the individualization of postoperative adjuvant chemotherapy with oral fluoropyrimidines for stage III colorectal cancer.
|
23232805 |
2013 |
|
Chronic graft-versus-host disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In addition, the TYMP genotype of donors was associated with the risk of chronic graft-versus-host disease (GVHD)-carriers of the minor allele being at an increased risk of developing this complication ([HR] = 1.7; P = 0.039).
|
23813863 |
2013 |
|
Stage III Colorectal Cancer AJCC v7
|
0.010 |
Biomarker
|
disease |
BEFREE |
The magnitude of the intratumoral TP/DPD enzyme ratio may be a potential indicator for the individualization of postoperative adjuvant chemotherapy with oral fluoropyrimidines for stage III colorectal cancer.
|
23232805 |
2013 |
|
Malignant Head and Neck Neoplasm
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Prior work in head and neck cancer showed that cell treatment with an inhibitor of the epidermal growth receptor (EGFR) gefitinib led to an increase in TP expression and sensitized them to 5'-DFUR.
|
21915635 |
2012 |
|
Stage IV Colorectal Cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
mRNA expression of TYMS, DPYD, and TYMP is associated with distinct characteristics and may be useful for predicting survival in patients with stage IV colorectal cancer.
|
22593457 |
2012 |